Quick Answer
BioAtla, Inc. reported Cash and Equivalents of $7.12 million for fiscal year 2025.
BioAtla, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $7.12M | -85.5% |
| 2024 | $49.05M | -56.0% |
| 2023 | $111.47M | -48.3% |
| 2022 | $215.51M | -12.0% |
| 2021 | $244.98M | +2.7% |
| 2020 | $238.60M | +6341.8% |
| 2019 | $3.70M | -65.9% |
| 2018 | $10.86M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.32M | -85.3% | -54.3% |
| June 30, 2025 | $18.21M | -70.5% | -43.7% |
| March 31, 2025 | $32.36M | -59.9% | -34.0% |
| December 31, 2024 | $49.05M | -56.0% | -13.2% |
| September 30, 2024 | $56.52M | -60.0% | -8.3% |
| June 30, 2024 | $61.66M | -63.4% | -23.5% |
| March 31, 2024 | $80.63M | -58.2% | -27.7% |
| December 31, 2023 | $111.47M | -48.3% | -21.1% |
- BioAtla, Inc. showed a decrease of -85.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, BioAtla, Inc.’s cash and equivalents has declined by 34.5% (from $10.86 million to $7.12 million).
- The most recent figure is from BioAtla, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: